Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

The vaccine includes hemagglutinin antigens from each of the four influenza strains. After injection, these antigens are processed by antigen‑presenting cells, stimulating the immune system to produce strain‑specific antibodies. The resulting humoral immunity enables the body to recognize and neutralize the corresponding viruses if exposure occurs.

The prescribed dose is determined by the treating healthcare professional. Typically, a single 0.5 mL injection is given intramuscularly or subcutaneously each influenza season. Patients should not self‑administer or alter the dose without medical guidance.

Safety data in pregnant or lactating women are limited. Vaccination may be considered when the potential benefits outweigh any theoretical risks. The decision should be made by a qualified healthcare provider based on individual clinical circumstances.

To place an order, submit an enquiry on the Influvac Tetra product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Influvac Tetra is a quadrivalent formulation, covering both B‑lineage viruses, whereas some alternatives are trivalent and omit one B strain. Its safety profile is comparable to other licensed influenza vaccines, with similar rates of mild injection‑site reactions. The broader strain coverage may offer enhanced protection in seasons where both B lineages circulate.

Influvac Tetra must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. Temperature monitoring during transport and storage is essential to maintain vaccine potency.

The vaccine is given as a single injection, usually into the deltoid muscle of the upper arm. Intramuscular administration is preferred, though subcutaneous injection may be used according to local guidelines. The procedure should be performed by a qualified healthcare professional using aseptic technique.

Serious adverse events are rare but may include anaphylaxis, severe allergic reactions, Guillain‑Barré syndrome, and high‑grade fever. If any of these symptoms develop after vaccination—such as difficulty breathing, swelling of the face or throat, rapid weakness, or persistent high fever—seek immediate medical attention.

Individuals with a known severe allergy to any component of the vaccine or who have experienced a previous severe reaction to an influenza vaccine should not receive Influvac Tetra. Vaccination should also be postponed in persons with moderate or severe acute illness until recovery.